Sand Jannie Marie, Larsen Lise, Hogaboam Cory, Martinez Fernando, Han Meilan, Røssel Larsen Martin, Nawrocki Arkadiusz, Zheng Qinlong, Karsdal Morten Asser, Leeming Diana Julie
Fibrosis Biology and Biomarkers, Nordic, Bioscience, Herlev, Denmark.
Department of Pathology, University of Michigan, Ann Arbor, Michigan, United States of America.
PLoS One. 2013 Dec 23;8(12):e84934. doi: 10.1371/journal.pone.0084934. eCollection 2013.
Fibrosis is characterized by excessive tissue remodeling resulting from altered expression of various growth factors, cytokines and proteases. We hypothesized that matrix metalloproteinase (MMP) mediated degradation of type IV collagen, a main component of the basement membrane, will release peptide fragments (neo-epitopes) into the circulation. Here we present the development of two competitive enzyme-linked immunosorbent assays (ELISAs) for assessing the levels of specific fragments of type IV collagen α1 (C4M12a1) and α3 (C4M12a3) chains in serum as indicators of fibrosis.
Fragments of type IV collagen cleaved in vitro by MMP-12 were identified by mass spectrometry, and two were chosen for ELISA development due to their unique sequences. The assays were evaluated using samples from a carbon tetrachloride (CCl₄) rat model of liver fibrosis and from patients with idiopathic pulmonary fibrosis (IPF) or chronic obstructive pulmonary disease (COPD).
Two technically robust ELISAs were produced using neo-epitope specific monoclonal antibodies. Mean serum C4M12a1 levels were significantly elevated in CCl₄-treated rats compared with controls in weeks 12, 16, and 20, with a maximum increase of 102% at week 16 (p < 0.0001). Further, C4M12a1 levels correlated with the total collagen content of the liver in CCl₄-treated rats (r = 0.43, p = 0.003). Mean serum C4M12a3 levels were significantly elevated in patients with mild, moderate, and severe IPF, and COPD relative to healthy controls, with a maximum increase of 321% in COPD (p < 0.0001).
Two assays measuring C4M12a1 and C4M12a3 enabled quantification of MMP mediated degradation of type IV collagen in serum. C4M12a1 was elevated in a pre-clinical model of liver fibrosis, and C4M12a3 was elevated in IPF and COPD patients. This suggests the use of these assays to investigate pathological remodeling of the basement membrane in different organs. However, validations in larger clinical settings are needed.
纤维化的特征是由于各种生长因子、细胞因子和蛋白酶表达改变导致的过度组织重塑。我们推测基质金属蛋白酶(MMP)介导的基底膜主要成分IV型胶原的降解会将肽片段(新表位)释放到循环中。在此,我们展示了两种竞争性酶联免疫吸附测定(ELISA)的开发,用于评估血清中IV型胶原α1(C4M12a1)和α3(C4M12a3)链的特定片段水平,作为纤维化的指标。
通过质谱鉴定MMP - 12在体外切割的IV型胶原片段,由于其独特序列选择了两个用于ELISA开发。使用来自四氯化碳(CCl₄)诱导的大鼠肝纤维化模型以及特发性肺纤维化(IPF)或慢性阻塞性肺疾病(COPD)患者的样本对测定进行评估。
使用新表位特异性单克隆抗体制备了两种技术上可靠的ELISA。在第12、16和20周时,CCl₄处理的大鼠血清C4M12a1平均水平与对照组相比显著升高,在第16周时最大升高102%(p < 0.000)。此外,CCl₄处理的大鼠中C4M12a1水平与肝脏总胶原含量相关(r = 0.43,p = 0.003)。与健康对照组相比,轻度、中度和重度IPF以及COPD患者的血清C4M12a3平均水平显著升高,COPD患者中最大升高321%(p < 0.0001)。
两种检测C4M12a1和C4M12a3的测定方法能够定量血清中MMP介导的IV型胶原降解。C4M12a1在肝纤维化临床前模型中升高,C4M12a3在IPF和COPD患者中升高。这表明可使用这些测定方法研究不同器官中基底膜的病理重塑。然而,需要在更大的临床环境中进行验证。